Clinical trials: Steatotic Liver Disease of Mixed Origin (MetALD)
Steatotic Liver Disease, Liver Fibrosis Progression in Chronic Liver Disease
Interventional AI-Human Collaboration for Steatotic Liver Disease Screening
Steatotic liver disease (SLD) is one of the most prevalent chronic liver diseases worldwide, affecting nearly 30% of the global population and projected to exceed 55% by 2040.
- Conditions
- Steatotic Liver Disease, Liver Fibrosis Progression in Chronic Liver Disease, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT07613827
- Testing
- AI-human collaboration for SLD screening
- Where
- China
- Volunteers
- 7,969 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Steatotic Liver Disease of Mixed Origin (MetALD)
Team Science (The Liver Health Study)
Liver damage from alcohol intake and weight-related behaviors is preventable and treatable only through lifestyle changes. This mixed-methods randomized controlled trial compares standard and enhanced approaches to screening…
- Trial name
- NCT06924281
- Testing
- Brief motivational interviewing with personalized feedback, Brief motivational interviewing with standard health information
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brown University
Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years.
- Conditions
- Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Steatotic Liver Disease of Mixed Origin (MetALD), ALD - Alcoholic Liver Disease
- Trial name
- LOVE (NCT06907563)
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 30,000 people
- Sponsor
- Universität des Saarlandes
Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease
Investigating Myosteatosis in Steatotic Liver Diseases
Steatotic liver diseases (SLD) are the most common chronic liver diseases worldwide. SLD are defined by an excessive liver lipid content (steatosis) of more than 5% of the total liver weight and includes 3 clinical entities …
- Conditions
- Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease of Mixed Origin (MetALD), Steatotic Liver Diseases
- Trial name
- MYO-SLD (NCT06514300)
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain